Literature DB >> 26991149

Simultaneous inference on treatment effects in survival studies with factorial designs.

Dan-Yu Lin1, Jianjian Gong2, Paul Gallo2, Paul H Bunn1, David Couper1.   

Abstract

A clinical trial with a 2×2 factorial design involves randomization of subjects to treatment A or A‾ and, within each group, further randomization to treatment B or B‾. Under this design, one can assess the effects of treatments A and B on a clinical endpoint using all patients. One may additionally compare treatment A, treatment B, or combination therapy AB to A‾B‾. With multiple comparisons, however, it may be desirable to control the overall type I error, especially for regulatory purposes. Because the subjects overlap in the comparisons, the test statistics are generally correlated. By accounting for the correlations, one can achieve higher statistical power compared to the conventional Bonferroni correction. Herein, we derive the correlation between any two (stratified or unstratified) log-rank statistics for a 2×2 factorial design with a survival time endpoint, such that the overall type I error for multiple treatment comparisons can be properly controlled. In addition, we allow for adjustment of prognostic factors in the treatment comparisons and conduct simultaneous inference on the effect sizes. We use simulation studies to show that the proposed methods perform well in realistic situations. We then provide an application to a recently completed randomized controlled clinical trial on alcohol dependence. Finally, we discuss extensions of our approach to other factorial designs and multiple endpoints.
© 2016, The International Biometric Society.

Entities:  

Keywords:  Censoring; Clinical trials; Correlated tests; Log-rank statistics; Multiple comparisons; Proportional hazards

Mesh:

Year:  2016        PMID: 26991149      PMCID: PMC5026867          DOI: 10.1111/biom.12507

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  9 in total

1.  Nonparametric inference in factorial designs with censored data.

Authors:  M G Akritas; M P LaValley
Journal:  Biometrics       Date:  1996-09       Impact factor: 2.571

2.  The analysis of multiple endpoints in clinical trials.

Authors:  S J Pocock; N L Geller; A A Tsiatis
Journal:  Biometrics       Date:  1987-09       Impact factor: 2.571

3.  Clinical trial methodology.

Authors:  R Peto
Journal:  Biomedicine       Date:  1978-09

4.  Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial.

Authors:  Koon K Teo; Marc Pfeffer; Giuseppe Mancia; Martin O'Donnell; Gilles Dagenais; Rafael Diaz; Antonio Dans; Lisheng Liu; Jackie Bosch; Philip Joseph; Ingrid Copland; Hyejung Jung; Janice Pogue; Salim Yusuf
Journal:  Eur Heart J       Date:  2014-03-09       Impact factor: 29.983

5.  Analysis of factorial survival experiments.

Authors:  E V Slud
Journal:  Biometrics       Date:  1994-03       Impact factor: 2.571

6.  Monitoring pairwise comparisons in multi-armed clinical trials.

Authors:  D A Follmann; M A Proschan; N L Geller
Journal:  Biometrics       Date:  1994-06       Impact factor: 2.571

7.  The 2 x 2 factorial design: its application to a randomized trial of aspirin and carotene in U.S. physicians.

Authors:  M J Stampfer; J E Buring; W Willett; B Rosner; K Eberlein; C H Hennekens
Journal:  Stat Med       Date:  1985 Apr-Jun       Impact factor: 2.373

8.  Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

Authors:  Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben
Journal:  JAMA       Date:  2006-05-03       Impact factor: 56.272

Review 9.  The women's health initiative: lessons learned.

Authors:  Ross L Prentice; Garnet L Anderson
Journal:  Annu Rev Public Health       Date:  2008       Impact factor: 21.981

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.